Psychedelics and the thalamocortical system: A scoping review
Sofía Villalba, Agustín Martínez Christensen, Lucia di Costanzo, Pablo Torterolo, Ignacio Carrera, Francisco J. Urbano, Verónica Bisagno
Pharmacology, Biochemistry, and Behavior July 9, 2026 DOI: 10.1016/j.pbb.2026.174232 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Scoping review Peer reviewed |
|---|---|
| Topics | Serotonin |
| Keywords | Thalamus Pathological Clinical practice Hallucinogen Nmda receptor |
| Key findings | Psychedelics affect thalamocortical connectivity, which may be important for clinical practice and understanding psychedelic neurobiology. |
Abstract
In recent years, psychedelics have shown promising results as therapeutic interventions for individuals with depression, terminal illnesses, substance use disorder, neurodegenerative diseases, trauma and obsessive-compulsive disorder. Moreover, research involving psychedelics have contributed to the understanding of the neurobiological mechanisms behind the "psychedelic state of consciousness" and to the physiological and pathological thalamocortical functioning. Also, there is evidence that several psychiatric conditions-such as depression, schizophrenia, bipolar disorder, and autism-are characterized by alterations in the thalamocortical system. Therefore, a deeper understanding of thalamic function could have significant implications for the psychedelic research field and for biological psychiatry. The aim of this scoping review (using the PRISMA method) was to synthesize the available evidence (preclinical and clinical) on the effects of psychedelics on the thalamocortical system that showed potential for clinical use (specifically NMDA receptor antagonists, serotonin 2 A receptor agonists and mixed-pharmacology compounds like iboga alkaloids). This review discussed findings regarding psychedelic administration and specific effects on thalamocortical connectivity suggesting its importance for clinical practice and for the understanding of psychedelic's neurobiology.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cites 61
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
and 56 more in the library